Clinical Trials

An Open-Label Phase 1/2 Study of JCARH125, BCMA targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma


Study ID
JUNO H125001

NCT Number
NCT03430011 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0766

Principle Investigator
Dr. David Siegel

Phase
I/II

Sponsor
Juno Therapeutics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now